Last reviewed · How we verify
Investigational COVID-19 Vaccine Lot B
Investigational COVID-19 Vaccine Lot B is a Biologic drug developed by ModernaTX, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Investigational COVID-19 Vaccine Lot B |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational COVID-19 Vaccine Lot B CI brief — competitive landscape report
- Investigational COVID-19 Vaccine Lot B updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI
Frequently asked questions about Investigational COVID-19 Vaccine Lot B
What is Investigational COVID-19 Vaccine Lot B?
Investigational COVID-19 Vaccine Lot B is a Biologic drug developed by ModernaTX, Inc..
Who makes Investigational COVID-19 Vaccine Lot B?
Investigational COVID-19 Vaccine Lot B is developed by ModernaTX, Inc. (see full ModernaTX, Inc. pipeline at /company/modernatx-inc).
What development phase is Investigational COVID-19 Vaccine Lot B in?
Investigational COVID-19 Vaccine Lot B is in Phase 2.